Data from the phase 3b STEP UP trial demonstrate that the 7.2 mg semaglutide dose provides superior weight reduction compared ...

Novo Nordisk’s 7.2 mg dose of Wegovy will compete against Lilly’s GLP-1 injection.

Doctors explain the differences between the Wegovy pill and injection in terms of efficacy, side effects, and more. They ...

The Food and Drug Administration (FDA) on Thursday approved a higher dose of the Wegovy weight loss drug. The manufacturer, ...

The high-dose Wegovy helped patients with obesity lose an average 20.7% of their weight after 72 weeks in a phase three trial.

The FDA approved a higher 7.2 mg dose of injectable semaglutide for adults with overweight and obesity, Novo Nordisk announced. Once-weekly injectable semaglutide 7.2 mg (Wegovy HD, Novo Nordisk) ...

Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved Wegovy ® HD (once-weekly injectable semaglutide 7.2 mg) to reduce excess body weight and maintain weight ...

The FDA approved a higher dose of the GLP-1 receptor agonist semaglutide for weight loss, dubbed Wegovy HD, the agency announced on Thursday. The once-weekly injectable will come in a 7.2-mg dose -- ...

Still basking in the afterglow of its Wegovy pill launch earlier this year, Novo has achieved another victory as it strives to make the most out of its blockbuster GLP-1 drug in an increasingly ...

The FDA has approved a new higher-dose version of injectable semaglutide (Wegovy HD, Novo Nordisk) for both weight loss and long-term weight-loss maintenance. The higher dose, 7.2 mg, produced an ...

In December 2025, the FDA approved the first-ever GLP-1 pill for chronic weight management - Novo Nordisk’s oral formulation ...

The Danish drugmaker on Thursday announced the approval of a 7.2 mg dose called Wegovy HD that will be available as a single-dose pen in the U.S. The company said the price of Wegovy HD will be ...